Novo Nordisk discovered how to optimize their mAb process
Posted on March 6, 2019
One of the key drivers for change in biopharmaceutical manufacturing is the need to reduce costs and increase the robustness and flexibility of manufacturing options. Optimization of downstream purification processes is an important step towards achieving these goals. One way to introduce cost and time efficiencies is with in-line concentration of dilute solutions before downstream processing steps.
Single-pass tangential flow filtration (SPTFF) technology has previously been used to cope with monoclonal antibody (mAb) production challenges. This study was built on behalf of Novo Nordisk to investigate the performance and scale-up possibilities for in-line concentration on a mAb production platform. It used a patented SPTFF system designed by Pall Biotech.
Subscribe to our FREE newsletter